Pantherna Therapeutics

About Pantherna Therapeutics

Pantherna Therapeutics is a privately-held biopharmaceutical company focused on developing first-in-class mRNA-based therapeutics with advanced lipid nanoparticle technologies for organ- and cell-selective delivery. The company targets vascular diseases by restoring endothelial function and enabling tissue-specific expression of therapeutic proteins, leveraging its PTXmRNA and PTXΔLNP platforms. Headquartered in Germany, with research operations in Berlin and Hennigsdorf, Pantherna aims to deliver systemic or targeted mRNA therapies for conditions such as pulmonary edema. Their work emphasizes delivery technology-driven drug development to advance vascular-focused therapies both locally and systemically.